TAZAROTENE: A Concise Review of Mechanism of Action and Therapeutic Benefits
Pharmaceutical Science-Drug review
DOI:
https://doi.org/10.22376/ijpbs/lpr.2022.12.6.P207-219Keywords:
Tazarotene, retinoid, psoriasis, acne vulgaris, and photoaging.Abstract
Tazarotene is the first topical receptor-selective retinoid prodrug derived from vitamin A, used for managing plaque psoriasis, and effective in acne vulgaris, and photoaging. The aim and objective of writing this article were to recapitulate the information from the literature regarding every aspect of tazarotene, recent research including clinical trials and analytical methods of detection along with general characteristics uses and information about the physicochemical characteristics, pharmacokinetics properties, mechanisms of action, treatment strategies, dosage and administration, drug interactions, safety profile, potential for teratogenicity and, use in special populations like paediatrics and pregnant women. We have also mentioned the analytical methods like hyphenated and conventional chromatographic techniques such as LC–MS/MS and HPTLC, HPLC respectively used to estimate this drug both qualitatively and quantitatively in pharmaceutical formulations for quality control purposes. The clinical data considered in this study concludes the effect of tazarotene in psoriasis, acne vulgaris, and in the condition of brittle nails in different regimens, conditions, and dosage forms, providing good insights for clinicians. The data compiled in this review contain all the information related to tazarotene already published in the literature, but the scattered form and recent studies, including clinical trials, new composition of lotions as well as cream forms, were not mentioned in previous reviews. This review focussed on the updated use of tazarotene as a viable option for treating psoriasis and other skin conditions alone and in combination with corticosteroids or phototherapy as approved by regulatory bodies. Due to minimum side effects, convenient once-daily application, rapid and sustained response, tazarotene is an optimum choice for various diseased skin conditions in combination with a corticosteroid in the treatment of psoriasis than tazarotene alone, as per the literature and clinical data summarized in this article.
References
Christophers E. Psoriasis-Epidemiology and clinical spectrum. Clin Exp Dermatol. 2001;26(4):314-20. doi: 10.1046/j.1365-2230.2001.00832.x, PMID 11422182.
Parisi R, Symmons DP, Griffiths CE, Ashcroft DM, Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: A systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377-85. doi: 10.1038/jid.2012.339, PMID 23014338.
Gibbs S. Skin disease and socioeconomic conditions in rural Africa: Tanzania. Int J Dermatol. 1996;35(9):633-9. doi: 10.1111/j.1365-4362.1996.tb03687.x, PMID 8876289.
Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the united states. J Am Acad Dermatol. 2014;70(3):512-6. doi: 10.1016/j.jaad.2013.11.013, PMID 24388724.
Danielsen K, Olsen AO, Wilsgaard T, Furberg AS. Is the prevalence of psoriasis increasing? A 30-year follow-up of a population-based cohort. Br J Dermatol. 2013;168(6):1303-10. doi: 10.1111/bjd.12230, PMID 23374051.
Di Meglio P, Villanova F, Nestle FO. Psoriasis. Cold Spring Harb Perspect Med. 2014;4(8):6. doi: 10.1101/cshperspect.a015354, PMID 25085957.
Harden JL, Krueger JG, Bowcock AM. The immunogenetics of psoriasis: A comprehensive review. J Autoimmun. 2015;64:66-73. doi: 10.1016/j.jaut.2015.07.008, PMID 26215033.
Liang Y, Sarkar MK, Tsoi LC, Gudjonsson JE. Psoriasis: A mixed autoimmune and autoinflammatory disease. Curr Opin Immunol. 2017;49:1-8. doi: 10.1016/j.coi.2017.07.007, PMID 28738209.
Sbidian E, Chaimani A, Garcia-Doval I, Do G, Hua C, Mazaud C et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2022;5:1465-858. doi: 10.1002/14651858.CD011535.pub2.
Zhou X, Chen Y, Cui L, Shi Y, Guo C. Advances in the pathogenesis of psoriasis: from keratinocyte perspective. Cell Death Dis. 2022;13(1):81. doi: 10.1038/s41419-022-04523-3, PMID 35075118.
Segaert S, Calzavara-Pinton P, de la Cueva P, Jalili A, Lons Danic D, Pink AE et al. Long-term topical management of psoriasis: the road ahead. J Dermatolog Treat. 2022;33(1):111-20. doi: 10.1080/09546634.2020.1729335, PMID 32091278.
Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CEM, Nast A, et al. Definition of treatment goals for moderate to severe psoriasis: A European consensus. Arch Dermatol Res. 2011;303(1):1-10. doi: 10.1007/s00403-010-1080-1, PMID 20857129.
Chat VS, Uppal SK, Kearns DG, Wu JJ. Clinical management of psoriasis patients during the COVID-19 pandemic. J Dermatolog Treat. 2022;33(2):1166-7. doi: 10.1080/09546634.2020.1781045, PMID 32568009.
Available from: https://www.emedicinehealth.com/understanding_psoriasis_medications/article_em.htm#medical_treatment_of_psoriasis.
Prussick R, Ebaugh BK. Psoriasis: an overview. Trauma. 2003;45(4):73-84.
Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Tazarotene.
Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Tazarotene#section=Computed-Properties.
Matsumoto RM, Sun H, Duff SB, Tang-Liu D. Skin distribution and metabolism of 14C-AGN 190168 in minipigs. Pharm Res. 1992;9;Suppl:289.
Franz TJ, Lehman PA, Franz S, LEWKAYA D, Matsumoto R, Tangliu D. Percutaneous-absorption of AGN 190168, A new synthetic retinoid, through human skin in vivo. [350 main st, malden, ma 02148 usa: Blackwell Publishing Inc]. J Invest Dermatol. 1992;98(4):650-.
Tang-Liu DD-S, Matsumoto RM, Usansky JI. Clinical pharmacokinetics and drug metabolism of tazarotene: a novel topical treatment for acne and psoriasis. Clin Pharmacokinet. 1999;37(4):273-87. doi: 10.2165/00003088-199937040-00001, PMID 10554045.
Lebwohl M, Ast E, Callen JP, Cullen SI, Hong SR, Kulp-Shorten CL, et al. Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis. J Am Acad Dermatol. 1998;38(5 Pt 1):705-11. doi: 10.1016/s0190-9622(98)70594-8, PMID 9591815.
Weinstein GD, Krueger GG, Lowe NJ, Duvic M, Friedman DJ, Jegasothy BV, et al. Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. J Am Acad Dermatol. 1997;37(1):85-92. doi: 10.1016/s0190-9622(97)70216-0, PMID 9216528.
Weinstein GD, Koo JY, Krueger GG, Lebwohl MG, Lowe NJ, Menter MA, et al. Tazarotene cream in the treatment of psoriasis: two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. J Am Acad Dermatol. 2003;48(5):760-7. doi: 10.1067/mjd.2003.103, PMID 12734506.
Study Report PK-95-048. Pharmacokinetics of AGN 190168 following single dose and multiple dose topical administration of 0.1% gel or 0.05% gel to subjects with stable plaque psoriasis. Irvine, (CA): Allergan; 1995.
Madhu C, Duff S, Baumgarten V, Rix P, Small D, Tang-Liu D. Metabolic de-esterification of tazarotene in human blood and rat and human liver microsomes. J Pharm Sci. 1997 Aug 1;86(8):972-4. doi: 10.1021/js9700558, PMID 9269878.
(Study Report PK-94-091. Effect of AGN 190168 on hepatic drug metabolising enzymes in Sprague-Dawley rats. Irvine, (CA): Allergan; 1995).
Marks R. Pharmacokinetics and safety review of tazarotene. J Am Acad Dermatol. 1998;39(4 Pt 2);Suppl(2):134-8. doi: 10.1016/s0190-9622(98)70310-x, PMID 9777791.
Allergan (US). Tazorac (tazarotene topical gel): prescribing information. Irvine, (CA); 2003.
Esgleyes-Ribot T, Chandraratna RA, Lew-Kaya DA, Sefton J, Duvic M. Response of psoriasis to a new topical retinoid, AGN 190168. J Am Acad Dermatol. 1994 Apr 1;30(4):581-90. doi: 10.1016/s0190-9622(94)70066-4, PMID 7512583.
Nagpal S, Patel S, Asano AT, Johnson AT, Duvic M, Chandraratna RA. Tazarotene-induced gene 1 (TIG1), a novel retinoic acid receptor-responsive gene in skin. J Invest Dermatol. 1996 Feb 1;106(2):269-74. doi: 10.1111/1523-1747.ep12340668, PMID 8601727.
Duvic M, Nagpal S, Asano AT, Chandraratna RAS. Molecular mechanisms of tazarotene action in psoriasis. J Am Acad Dermatol. 1997;37(2 Pt 3):S18-24. doi: 10.1016/S0190-9622(97)80396-9, PMID 9270552.
Christophers E. Psoriasis-epidemiology and clinical spectrum. Clin Exp Dermatol. 2001;26(4):314-20. doi: 10.1046/j.1365-2230.2001.00832.x, PMID 11422182.
Menter A. Pharmacokinetics and safety of tazarotene. J Am Acad Dermatol. 2000;43(2 Pt 3):S31-5. doi: 10.1067/mjd.2000.108321, PMID 10898827.
Esgleyes-Ribot T, Chandraratna RA, Lew-Kaya DA, Sefton J, Duvic M. Response of pso- riasis to a new topical retinoid, AGN 190168. J Am Acad Dermatol. 1994;30(4):581-90. doi: 10.1016/s0190-9622(94)70066-4, PMID 7512583.
Nonomura K, Yamanishi K, Yasuno H, Nara K, Hirose S. Up-regulation of elafin/SKALP gene expression in psoriatic epidermis. J Invest Dermatol. 1994;103(1):88-91. doi: 10.1111/1523-1747.ep12391802, PMID 8027586.
Hecker D, Worsley J, Yueh G, Kuroda K, Lebwohl M. Interactions between tazarotene and ultraviolet light. J Am Acad Dermatol. 1999;41(6):927-30. doi: 10.1016/s0190-9622(99)70248-3, PMID 10570375.
Krueger GG, Drake LA, Elias PM, Lowe NJ, Guzzo C, Weinstein GD, et al. The safety and efficacy of tazarotene gel, a topical acetylenic retinoid, in the treatment of psoriasis. Arch Dermatol. 1998 Jan 1;134(1):57-60. doi: 10.1001/archderm.134.1.57, PMID 9449910.
Weinstein GD, Green L, Drake LA, Elias PM, Krueger GG, Lazarus GS, et al. New topical retinoid gel for therapy of psoriasis-dose-ranging study of AGN 190168. J Invest Dermatol. 1993;100(4):544-.
Hager C, Mays S, Chandraratna R. Tazarotene: a topical retinoid with efficacy in psoriasis vulgaris and scalp psoriasis. Australas J Dermatol. 1997;2:149-50.
Weinstein GD, Krueger GG, Lowe NJ, Duvic M, Friedman DJ, Jegasothy BV, et al. Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. J Am Acad Dermatol. 1997 Jul 1;37(1):85-92. doi: 10.1016/s0190-9622(97)70216-0, PMID 9216528.
Weinstein GD. Tazarotene gel: efficacy and safety in plaque psoriasis. J Am Acad Dermatol. 1997 Aug 1;37(2 Pt 3):S33-8. doi: 10.1016/S0190-9622(97)80398-2, PMID 9270554.
Xi C, Xiong C, Wang H, Liu Y, Luo S. Combination of retinoids and narrow-band ultraviolet B inhibits matrix metalloproteinase 13 expression in HaCaT keratinocytes and a mouse model of psoriasis. Sci Rep. 2021 Jun 25;11(1):13328. doi: 10.1038/s41598-021-92599-w, PMID 34172768.
Apisarnthanarax N, Talpur R, Ward S, Ni X, Kim HW, Duvic M. Tazarotene 0.1% gel for refractory mycosis fungoides lesions: an open-label pilot study. J Am Acad Dermatol. 2004 Apr;50(4):600-7. doi: 10.1016/j.jaad.2003.09.005, PMID 15034511.
Lowe N, Horwitz S, Tanghetti E, Draelos Z, Menter A. Tazarotene versus tazarotene plus hydroquinone in the treatment of photodamaged facial skin: a multicenter, double-blind, randomized study. J Cosmet Laser Ther. 2006 Sep;8(3):121-7. doi: 10.1080/14764170600895237, PMID 16971360.
Kaidbey K, Kopper SC, Sefton J, Gibson JR. A pilot study to determine the effect of tazarotene gel 0.1% on steroid-induced epidermal atrophy. Int J Dermatol. 2001 Jul;40(7):468-71. doi: 10.1046/j.1365-4362.2001.01234.x, PMID 11679006.
Kang S, Leyden JJ, Lowe NJ, Ortonne JP, Phillips TJ, Weinstein GD, et al. Tazarotene cream for the treatment of facial photodamage: a multicenter, investigator-masked, randomized, vehicle-controlled, parallel comparison of 0.01%, 0.025%, 0.05%, and 0.1% tazarotene creams with 0.05% tretinoin emollient cream applied once daily for 24 weeks. Arch Dermatol. 2001 Dec;137(12):1597-604. doi: 10.1001/archderm.137.12.1597, PMID 11735710.
Kakita L. Tazarotene versus tretinoin or adapalene in the treatment of acne vulgaris. J Am Acad Dermatol. 2000;43(2 Pt 3):S51-4. doi: 10.1067/mjd.2000.108322, PMID 10898831.
Webster GF, Berson D, Stein LF, Fivenson DP, Tanghetti EA, Ling M. Efficacy and tolerability of once-daily tazarotene 0.1% gel versus once-daily tretinoin 0.025% gel in the treatment of facial acne vulgaris: a randomized trial. Cutis. 2001 Jun 1;67(6);Suppl:4-9. PMID 11499329.
Leyden JJ, Tanghetti EA, Miller B, Ung M, Berson D, Lee J. Once-daily tazarotene 0.1% gel versus once-daily tretinoin 0.1% microsponge gel for the treatment of facial acne vulgaris: a double-blind randomized trial. Cutis. 2002 Feb 1;69(2);Suppl:12-9. PMID 12095064.
Webster GF, Guenther L, Poulin YP, Solomon BA, Loven K, Lee J. A multicenter, double-blind, randomized comparison study of the efficacy and tolerability of once-daily tazarotene 0.1% gel and adapalene 0.1% gel for the treatment of facial acne vulgaris. Cutis. 2002 Feb 1;69(2);Suppl:4-11. PMID 12095066.
Bershad S, Kranjac Singer GK, Parente JE, Tan MH, Sherer DW, Persaud AN, et al. Successful treatment of acne vulgaris using a new method: results of a randomized vehicle-controlled trial of short-contact therapy with 0.1% tazarotene gel. Arch Dermatol. 2002 Apr 1;138(4):481-9. doi: 10.1001/archderm.138.4.481, PMID 11939810.
Krueger GG, Drake LA, Elias PM, Lowe NJ, Guzzo C, Weinstein GD, et al. The safety and efficacy of tazarotene gel, a topical acetylenic retinoid, in the treatment of psoriasis. Arch Dermatol. 1998;134(1):57-60. doi: 10.1001/archderm.134.1.57, PMID 9449910.
Katz HI. Topical corticosteroids. Dermatol Clin. 1995;13(4):805-15. doi: 10.1016/S0733-8635(18)30044-5, PMID 8785885.
Green L, Sadoff W. A clinical evaluation of tazarotene 0.1% gel, with and without a high- or mid-high-potency corticosteroid, in patients with stable plaque psoriasis. J Cutan Med Surg. 2002;6(2):95-102. doi: 10.1007/s10227-001-0031-z, PMID 11992180.
Koo JY, Martin D. Investigator-masked comparison of tazarotene gel q.d. plus mometasone furoate cream q.d. versus mometasone furoate cream b.i.d. in the treatment of plaque psoria- sis. Int J Dermatol. 2001;40(3):210-2. doi: 10.1046/j.1365-4362.2001.01167.x, PMID 11422529.
Guenther LC, Poulin YP, Pariser DM. A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1 % cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis. Clin Ther. 2000;22(10):1225-38. doi: 10.1016/s0149-2918(00)83065-9, PMID 11110233.
Lowe NJ. Ultraviolet B phototherapy plus topical retinoid therapy. Cutis. 1999;63:6-7.
Behrens S, Grundmann-Kollmann M, Schiener R, Peter RU, Kerscher M. Combination therapy of psoriasis with narrow-band UVB irradiation and topical tazarotene gel. J Am Acad Dermatol. 2000;42(3):493-5. doi: 10.1016/s0190-9622(00)90225-1, PMID 10688723.
Behrens S, Grundmann-Kollmann M, Peter RU, Kerscher M. Combination treatment of psoriasis with photochemotherapy and tazarotene gel, a receptor-selective topical retinoid. Br J Dermatol. 1999;141(1):177. doi: 10.1046/j.1365-2133.1999.02951.x, PMID 10417841.
Koo JY, Lowe NJ, Lew-Kaya DA, Vasilopoulos AI, Lue JC, Sefton J, et al. Tazarotene plus UVB phototherapy in the treatment of psoriasis. J Am Acad Dermatol. 2000;43(5 Pt 1):821-8. doi: 10.1067/mjd.2000.107940, PMID 11050587.
Taylor CR, Stern RS, Leyden JJ, Gilchrest BA. Photoaging/photodamage and photoprotection. J Am Acad Dermatol. 1991;22:315-7.
Stern RS, Laird N. The carcinogenic risk of treatments for severe psoriasis: photochemotherapy follow-up study. Cancer. 1994;73(11):2759-64. doi: 10.1002/1097-0142(19940601)73:11<2759::aid-cncr2820731118>3.0.co;2-c, PMID 8194017.
Allergan (US). Tazorac® (tazarotene topical cream): prescribing information. Irvine, (CA); 2001.
Allergan Ltd (UK). Zorac 0.05% Gel: Summary of Product Characteristics [online]. Available from: http://emc.medicines.org.uk.
Allergan Ltd (UK). Zorac 0.1% Gel: Summary of Product Characteristics [online]. Available from: http://emc.medicines.org.uk.
Marks R. Clinical safety of tazarotene in the treatment of plaque psoriasis. J Am Acad Dermatol. 1997 Aug;37(2 Pt 3):S25-32, PMID 9270553.
Shalita AR, Chalker DK, Griffith RF, Herbert AA, Hickman JG, Maloney JM, et al. Tazarotene gel is safe and effective in the treatment of acne vulgaris: a multicenter, double-blind, vehicle-controlled study. Cutis. 1999;63(6):349-54. PMID 10388959.
NDA 20-600. Approved June 13, 1997.
Duvic M. Tazarotene: a review of its pharmacological profile and potential for clinical use in psoriasis. Exp Opin Investig Drugs. 1997;6(10):1537-51. doi: 10.1517/13543784.6.10.1537, PMID 15989518.
Chandraratna RAS. Tazarotene: the first receptor-selective topical retinoid for the treatment of plaque psoriasis. J Am Acad Dermatol. 1997;37(2 Pt 3);Suppl:S12-7. doi: 10.1016/S0190-9622(97)80395-7, PMID 9270551.
Peris K, Fargnoli MC, Chimenti S. Preliminary observations on the use of topical tazarotene to treat basal-cell carcinoma. N Engl J Med. 1999;341(23):1767-8. doi: 10.1056/NEJM199912023412312, PMID 10610445.
Available from: https://go.drugbank.com/drugs/DB00799.
Duvic M. Tazarotene: a review of its pharmacological profile and potential for clinical use in psoriasis. Expert Opin Investig Drugs. 1997;6(10):1537-51. doi: 10.1517/13543784.6.10.1537, PMID 15989518.
Gaikwad J, Sharma S, Hatware KV. Review on characteristics and analytical methods of tazarotene: an update. Crit Rev Anal Chem. 2020;50(1):90-6. doi: 10.1080/10408347.2019.1586519, PMID 30942085.
Sherber NS, Hoch AM, Coppola CA, Carter EL, Chang HL, Barsanti FR, et al. efficacy and safety study of tazarotene cream 0.1% for the treatment of brittle nail syndrome. Cutis. 2011;87(2):96-103. PMID 21416778.
Available from: https://clinicaltrials.gov/ct2/show/NCT01094717.
Tang JY, Chiou AS, Mackay-Wiggan JM, Aszterbaum M, Chanana AM, Lee W, et al. Tazarotene: randomized, double-blind, vehicle-controlled, and open-label concurrent trials for basal cell carcinoma prevention and therapy in patients with basal cell nevus syndrome. Cancer Prev Res (Phila). 2014;7(3):292-9. doi: 10.1158/1940-6207.CAPR-13-0305, PMID 24441673.
Hyde MA, Hadley ML, Tristani-Firouzi P, Goldgar D, Bowen GM. A randomized trial of the off-label use of imiquimod, 5%, cream with vs without tazarotene, 0.1%, gel for the treatment of lentigo maligna, followed by conservative staged excisions. Arch Dermatol. 2012;148(5):592-6. doi: 10.1001/archdermatol.2012.270, PMID 22431716.
Leyden J, Thiboutot DM, Shalita AR, Webster G, Washenik K, Strober BE, et al. comparison of tazarotene and minocycline maintenance therapies in acne vulgaris: a multicenter, double-blind, randomized, parallel-group study. Arch Dermatol. 2006;142(5):605-12. doi: 10.1001/archderm.142.5.605, PMID 16702498.
Available from: https://clinicaltrials.gov/ct2/show/NCT03599193.
Available from: https://clinicaltrials.gov/ct2/show/results/NCT03341910.
Epstein EL, Stein Gold L. Safety and efficacy of tazarotene foam for the treatment of acne vulgaris. Clin Cosmet Investig Dermatol. 2013;6:123-5. doi: 10.2147/CCID.S34054, PMID 23696711.
Berg JE, Bowman JP, Saenz AB. Cumulative irritation potential and contact sensitization potential of tazarotene foam 0.1% in 2 phase 1 patch studies. Cutis. 2012;90(4):206-11. PMID 23259209.
Feldman SR, Werner CP, Alió Saenz AB. The efficacy and tolerability of tazarotene foam, 0.1%, in the treatment of acne vulgaris in 2-multicenter, randomized, vehicle-controlled, double-blind studies. J Drugs Dermatol. 2013;12(4):438-46. PMID 23652892.
Dhawan SS, Gwazdauskas J. Clindamycin phosphate 1.2%-benzoyl peroxide (5% or 2.5%) plus tazarotene cream 0.1% for the treatment of acne. Cutis. 2013;91(2):99-104. PMID 23513559.
Available from: https://clinicaltrials.gov/ct2/show/NCT00834210.
Tanghetti E, Dhawan S, Green L, Del Rosso J, Draelos Z, Leyden J, et al. Randomized comparison of the safety and efficacy of tazarotene 0.1% cream and adapalene 0.3% gel in the treatment of patients with at least moderate facial acne vulgaris. J Drugs Dermatol. 2010;9(5):549-58. PMID 20480800.
He C, Jin H, Liu X, Hu F, Zhang L, Zhang S, et al. Tazarotene/betamethasone dipropionate cream in patients with plaque psoriasis: results of a prospective, multicenter, observational study. Dermatology. 2021;237(4):603-10. doi: 10.1159/000511891, PMID 33352561.
Chen H, Sun J, Yang H, Sun Q, Zhang J, Gu J, et al. Fixed combination of tazarotene and betamethasone dipropionate for treatment of psoriasis vulgaris: the result of a phase 3, multicenter, randomized controlled trial. J Dermatol. 2020;47(7):728-34. doi: 10.1111/1346-8138.15349, PMID 32346959.
Available from: https://clinicaltrials.gov/ct2/show/NCT05314127.
Stein Gold L, Kircik L, Baldwin H, Callender V, Tanghetti E, Del Rosso J, et al. Tazarotene 0.045% lotion for females with acne: analysis of two adult age groups. J Drugs Dermatol. 2022;21(6):587-95. doi: 10.36849/JDD.6876, PMID 35674760.
Mohney LA, Singh R, Feldman SR. Tazarotene 0.045% lotion: A novel retinoid formulation. Ann Pharmacother. 2022;56(10):1174-80. doi: 10.1177/10600280211072155, PMID 35112585.
Available from: https://www.drugs.com/ingredient/tazarotene.html.
Published
How to Cite
Issue
Section
Copyright (c) 2022 Chahat Khanna, Peeyush Sharma, Simranjit Kaur, Sukhdeep Singh, Sandeep Rahar, Lavish Kumar, Varinder Soni, Charanjeet Kaur, Parminderjit Kaur, Charanjit Kaur
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
